Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.70 USD
+0.01 (1.15%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-1.71%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Income Statements
Fiscal Year end for Turnstone Biologics Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 19 | 73 | 101 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 19 | 73 | 101 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 78 | 105 | 68 | 0 | 0 |
Income After Depreciation & Amortization | -59 | -32 | 33 | 0 | 0 |
Non-Operating Income | 4 | 1 | 1 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -55 | -31 | 34 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -55 | -31 | 33 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -55 | -31 | 33 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -58 | -28 | 35 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 1 | 4 | 2 | NA | NA |
Income After Depreciation & Amortization | -59 | -32 | 33 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 11.56 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -4.78 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -4.78 | -12.49 | NA | NA | NA |
Fiscal Year end for Turnstone Biologics Corp falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 22.06 | 20.69 | 17.86 | 18.93 | 21.85 |
Income After SG&A, R&D, and Dept/Amort Expenses | -22.06 | -20.69 | -17.86 | -18.93 | -21.85 |
Non-Operating Income | 0.76 | 1.08 | 1.24 | 1.58 | 0.35 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -21.30 | -19.61 | -16.62 | -17.35 | -21.51 |
Income Taxes | 0.00 | 0.02 | -0.17 | -0.03 | -0.01 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -21.30 | -19.63 | -16.45 | -17.32 | -21.50 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.30 | -19.63 | -16.45 | -17.32 | -21.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 23.04 | 23.01 | 22.94 | 17.40 | 2.85 |
Diluted EPS Before Non-Recurring Items | -0.92 | -0.85 | -0.73 | -1.00 | -7.56 |
Diluted Net EPS (GAAP) | -0.92 | -0.85 | 3.78 | -1.00 | -7.56 |